Lupus nephritis: NLRP3 inflammasome ignites podocyte dysfunction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Endosome traffic in rheumatic diseases: mechanistic insights and therapeutic opportunities.Nature reviews. Rheumatology · 2026
   Review
2. NLRP3 Inflammasome as Potential Predictor of Non-Responsiveness to Immunosuppressive Treatment in Lupus Nephritis.International journal of molecular sciences · 2025
   Article
3. The intelligent podocyte: sensing and responding to a complex microenvironment.Nature reviews. Nephrology · 2025
   Review
4. Traditional Chinese medicine for lupus nephritis: modulation of autoimmune pathogenesis.Frontiers in pharmacology · 2025
   Review
5. Inflammasomes and idiopathic inflammatory myopathies.Frontiers in immunology · 2024
   Review
6. Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis.Cell death & disease · 2023
   Article
7. No NLRP3 inflammasome activity in kidney epithelial cells, not even when the NLRP3-A350V Muckle-Wells variant is expressed in podocytes of diabetic mice.Frontiers in immunology · 2023
   Article
8. Renal and Inflammatory Proteins as Biomarkers of Diabetic Kidney Disease and Lupus Nephritis.Oxidative medicine and cellular longevity · 2022
   Article
9. Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling.Mediators of inflammation · 2022
   Article
10. Novel Effects of Combination Therapy Through Inhibition of Caspase-1/Gasdermin D Induced-Pyroptosis in Lupus Nephritis.Frontiers in immunology · 2021
    Article
11. The role of inflammasomes in kidney disease.Nature reviews. Nephrology · 2019
    Review
12. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.Clinical immunology (Orlando, Fla.) · 2018
    Article

Corrections and comments

• Comment on
  Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as